Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Actinium Pharmaceuticals, Inc. (ATNM) had Return on Tangible Equity of -75.82% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-5.94M |
|
-- |
|
-- |
|
$6.41M |
|
$-6.41M |
|
$0.47M |
|
$-5.94M |
|
$-5.94M |
|
$-5.94M |
|
$-5.94M |
|
$-5.94M |
|
$-5.94M |
|
$-6.41M |
|
$-6.21M |
|
31.20M |
|
31.20M |
|
$-0.20 |
|
$-0.20 |
|
| Balance Sheet Financials | |
$49.38M |
|
$0.29M |
|
$2.39M |
|
$51.77M |
|
$7.97M |
|
-- |
|
$35.97M |
|
$43.94M |
|
$7.83M |
|
$7.83M |
|
$7.83M |
|
31.20M |
|
| Cash Flow Statement Financials | |
$-24.58M |
|
$-0.10M |
|
$-0.22M |
|
$73.23M |
|
$48.33M |
|
$-24.89M |
|
$9.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.20 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.68M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-75.82% |
|
|
Return on Tangible Equity |
-75.82% |
-11.47% |
|
-75.82% |
|
$0.25 |
|
$-0.79 |
|
$-0.79 |
|